End-of-day quote
Pakistan S.E.
06:00:00 2024-04-25 pm EDT
|
5-day change
|
1st Jan Change
|
577.6
PKR
|
+0.50%
|
|
+5.41%
|
+25.51%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
61,780
|
43,740
|
73,951
|
70,244
|
45,358
|
45,055
|
Enterprise Value (EV)
1 |
56,316
|
41,364
|
67,278
|
61,869
|
36,814
|
40,176
|
P/E ratio
|
22.9
x
|
33.6
x
|
16.3
x
|
11.8
x
|
15.1
x
|
172
x
|
Yield
|
3.17%
|
1.68%
|
5.3%
|
5.57%
|
3.24%
|
-
|
Capitalization / Revenue
|
2.08
x
|
1.45
x
|
2.1
x
|
1.65
x
|
0.92
x
|
0.81
x
|
EV / Revenue
|
1.89
x
|
1.37
x
|
1.91
x
|
1.45
x
|
0.75
x
|
0.72
x
|
EV / EBITDA
|
11.2
x
|
12.4
x
|
10.1
x
|
6.77
x
|
5.01
x
|
10.1
x
|
EV / FCF
|
80.5
x
|
-29.7
x
|
11.9
x
|
11.7
x
|
9.7
x
|
-16.3
x
|
FCF Yield
|
1.24%
|
-3.36%
|
8.42%
|
8.53%
|
10.3%
|
-6.14%
|
Price to Book
|
4.67
x
|
3.27
x
|
4.74
x
|
4.05
x
|
2.65
x
|
2.47
x
|
Nbr of stocks (in thousands)
|
97,900
|
97,900
|
97,900
|
97,900
|
97,900
|
97,900
|
Reference price
2 |
631.0
|
446.8
|
755.4
|
717.5
|
463.3
|
460.2
|
Announcement Date
|
3/29/19
|
3/27/20
|
3/31/21
|
3/17/22
|
3/29/23
|
3/30/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
29,719
|
30,156
|
35,283
|
42,570
|
49,258
|
55,475
|
EBITDA
1 |
5,019
|
3,338
|
6,649
|
9,135
|
7,353
|
3,966
|
EBIT
1 |
4,282
|
2,447
|
5,666
|
8,006
|
6,011
|
2,468
|
Operating Margin
|
14.41%
|
8.11%
|
16.06%
|
18.81%
|
12.2%
|
4.45%
|
Earnings before Tax (EBT)
1 |
4,344
|
2,511
|
6,244
|
8,410
|
6,148
|
2,590
|
Net income
1 |
2,694
|
1,300
|
4,535
|
5,967
|
3,004
|
261.8
|
Net margin
|
9.07%
|
4.31%
|
12.85%
|
14.02%
|
6.1%
|
0.47%
|
EPS
2 |
27.52
|
13.28
|
46.33
|
60.95
|
30.69
|
2.674
|
Free Cash Flow
1 |
699.8
|
-1,392
|
5,664
|
5,279
|
3,796
|
-2,467
|
FCF margin
|
2.35%
|
-4.61%
|
16.05%
|
12.4%
|
7.71%
|
-4.45%
|
FCF Conversion (EBITDA)
|
13.94%
|
-
|
85.18%
|
57.79%
|
51.62%
|
-
|
FCF Conversion (Net income)
|
25.97%
|
-
|
124.88%
|
88.47%
|
126.35%
|
-
|
Dividend per Share
2 |
20.00
|
7.500
|
40.00
|
40.00
|
15.00
|
-
|
Announcement Date
|
3/29/19
|
3/27/20
|
3/31/21
|
3/17/22
|
3/29/23
|
3/30/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
5,464
|
2,376
|
6,673
|
8,376
|
8,545
|
4,878
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
700
|
-1,392
|
5,664
|
5,279
|
3,796
|
-2,467
|
ROE (net income / shareholders' equity)
|
19.5%
|
9.77%
|
31.3%
|
36.2%
|
17.4%
|
1.48%
|
ROA (Net income/ Total Assets)
|
13.6%
|
7.45%
|
15.5%
|
18.7%
|
12%
|
4.37%
|
Assets
1 |
19,870
|
17,442
|
29,246
|
31,889
|
24,984
|
5,992
|
Book Value Per Share
2 |
135.0
|
137.0
|
159.0
|
177.0
|
175.0
|
186.0
|
Cash Flow per Share
2 |
58.00
|
28.20
|
76.50
|
8.370
|
81.40
|
46.40
|
Capex
1 |
2,539
|
1,868
|
1,380
|
2,055
|
3,585
|
3,075
|
Capex / Sales
|
8.54%
|
6.19%
|
3.91%
|
4.83%
|
7.28%
|
5.54%
|
Announcement Date
|
3/29/19
|
3/27/20
|
3/31/21
|
3/17/22
|
3/29/23
|
3/30/24
|
|
1st Jan change
|
Capi.
|
---|
| +25.51% | 203M | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|